Crescita Therapeutics Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was CAD 5.16 million compared to CAD 6.51 million a year ago. Net loss was CAD 0.281 million compared to CAD 0.037 million a year ago. Basic loss per share from continuing operations was CAD 0.01.
For the six months, revenue was CAD 9.76 million compared to CAD 11.46 million a year ago. Net loss was CAD 0.554 million compared to CAD 0.511 million a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.02 a year ago.